Janet B. McGill, M.D.
Associate Professor of Medicine
| Office Location: | 4570 Children's Place | |
| Mailing Address: | 660 S. Euclid Ave. Campus Box 8127 St. Louis, MO 63110 |
|
| Phone: | (314) 362-8688 | |
| Fax: | (314) 362-4833 | |
| E-mail Address: |
 |
Biography
Dr. McGill completed her internship, residency and was chief resident at William Beaumont Hospital in Royal Oak Michigan. After her fellowship in Endocrinology at Washington University, she joined the faculty in 1987. She has been an active clinical researcher in diabetes for over 20 years, beginning with the DCCT and Lewis study of ACE-inhibition in diabetic nephropathy. Currently, Dr. McGill is the PI on clinical trials investigating new treatments for diabetes and its complications. She collaborates with cardiologists in studies of myocardial fuel metabolism, a multi-specialty group studying atheroma reduction in the metabolic syndrome, and psychiatrists in the study of the interaction of diabetes and depression. She has served on steering and safety committees for international multi-centered clinical trials, including RENAAL, TREAT, FOCAL, KEEP and the SUN studies in diabetic nephropathy. Dr. McGill is co-director of the Prevention and Control Core of the DRTC at Washington University.
Research Interests
Diabetes affects 8% of the US population, and has devastating long term effects that both shorten life and greatly alter the quality of life. The treatment of diabetes has improved with the advent of newer therapies that target multiple metabolic pathways. Nonetheless, patients often face severe consequences of vision loss, end stage kidney disease, cardiovascular disease and are at increased risk for depression. Along with testing new therapies for hyperglycemia, my interest has been to explore the pathways by which glucose causes damaging effects, and pursue therapies that might intervene in these pathways. My clinical research staff includes four nurses, a social worker, an administrator, a dietitian and medical assistants who have years of experience doing both investigator-initiated and multi-centered clinical trials.
An important area of ongoing clinical investigation includes collaboration with Dr. Gropler of the CVIL laboratory in the study of myocardial fuel metabolism and its functional correlates by PET, ECHO and MRI in patients with diabetes. We are engaged in a novel study designed by Dr. Semenkovich testing whether chloroquine will reduce atheroma burden in patients with the metabolic syndrome. In another creative approach, we are testing whether reduction of inflammation with salsalate will improve glycemic control in patients with type 2 diabetes. Studies of complications include investigational agents to reduce the progression of kidney disease, and outcome trials in high-risk populations of diabetic patients with CKD. Recent trials of interventions for retinopathy and neuropathy have been completed.
As co-director of the Prevention and Control Core of the Diabetes Research and Training Center at Washington University, I am working on ways to make clinical research in diabetes more efficient and effective by enhancing recruitment, setting up standard data sets and improving communication with the community.
Awards and Honors
Best Doctor, 2001-2007
(Current Clinical Study)
